GleamWall
中文EN

ENSC Ensysce Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1716947 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY37.9%
TTM net income YoY-729.4%
TTM EPS YoY-18.3%
Revenue 3-yr CAGR25.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,477.0%
Net margin-1,470.4%
FCF margin—
EBITDA margin-1,476.6%

Returns

ROE-635.4%
ROA-533.3%
ROIC (approx.)—
Asset turnover0.36x

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.02x
Interest coverage-7,157.58x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-484.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$5.07M$5.21M
R&D expense$10.38M$7.22M
SG&A expense$4.93M$4.72M
Operating income-$10.24M-$6.73M
Interest expense$18,767$1.29M
Net income-$10.18M-$7.99M
EBITDA-$10.23M-$6.73M
EPS (basic)-3.98-11.45
EPS (diluted)-3.98-11.45
Weighted avg. shares (diluted)2.56M697,686
Balance sheet
Cash & equivalents$4.31M$3.50M
Current assets$7.25M$5.34M
PP&E, net$124,129—
Total assets$7.45M$5.60M
Current liabilities$4.57M$2.21M
Total liabilities$4.57M$2.22M
Shareholders' equity$3.21M$3.71M
Shares outstanding4.57M1.36M
Cash flow statement
Operating cash flow-$7.81M-$7.50M
Capital expenditure$123,643—
Free cash flow-$7.93M—
Investing cash flow-$123,643—
Financing cash flow$8.74M$9.88M
Depreciation & amortization$6,533$0
Stock-based compensation$177,086$110,723

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.